EUCTR2019-003236-23-CZ进行中（未招募）1 期
A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent infection with HPV Types 16, 18, 31, 33, 45, 52, or 58 in adult males, 20 to 45 years of age - Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 6,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Is healthy and is judged to be in good physical health based on medical history and physical examination
- •2.Is male, from 20 years to 45 years of age inclusive, at the time of signing the informed consent
- •3.Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.
- •4.Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or email) for follow-up purposes
- •5.Can read, understand, and complete the eVRC
- •6.Has had at least 1 lifetime sexual partner
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 6000
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Has a history of HPV-related anal lesion (anal intraepithelial neoplasia or anal cancer) or HPV-related head and neck cancer
- •2.Has a history of or clinical evidence at the Day 1 external genital examination of HPV-related external lesion (condyloma acuminata, penile intraepithelial neoplasia or penile cancer)
- •3.Has clinical evidence at the Day 1 external genital examination of gross genital lesion suggesting sexually transmitted disease
- •4.Has a fever (defined as oral temperature =100.0°F or =37.8°C) within the 24-hour period prior to the Day 1 visit*
- •5.Has a history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention
- •6.Is allergic to any vaccine component, including aluminum, yeast, or BENZONASE™ (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]). For this exclusion criterion, an allergy to vaccine components is defined as an allergic reaction that met the criteria for severe AEs or SAEs
- •7.Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections
- •8.Is currently immunocompromised or has been diagnosed as having congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition
- •9.Has a history of splenectomy
- •10.Has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate by judgement of investigator
- •11.Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the investigator. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use
- •12.Has received within 12 months prior to enrollment, is receiving, or plans to receive during Day 1 through Month 7 of the study, the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (AravaTM), TNF-a antagonists, monoclonal antibody therapies (including rituximab [Rituxan™]), IVIG, antilymphocyte sera, or other therapy known to interfere with the immune response. Regarding systemic corticosteroids, a participant will be excluded if he is currently receiving steroid therapy, has recently (defined as within 2 weeks of Day 1 vaccination) received such therapy, or has received 2 or more courses of high-dose corticosteroids (=20 mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal, or topical steroids are considered eligible for the study.
- •13.Has received within the 3 months prior to the Day 1 vaccination, is receiving, or plans to receive during Day 1 through Month 7 of the study, any immune globulin product (including RhoGAM™ [Ortho-Clinical Diagnostics]) or blood-derived product other than IVIG
- •14.Has received inactivated or recombinant vaccines within 14 days prior to Day 1 vaccination or receipt of live vac
研究者
相似试验
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageMedDRA version: 20.1Level: LLTClassification code: 10063001Term: Human papilloma virus infection Class: 10021881Prevention of oral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58CTIS2022-501974-21-00Merck Sharp & Dohme LLC6,033
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageEUCTR2019-003236-23-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc6,000
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageOral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58MedDRA version: 20.0Level: LLTClassification code 10006524Term: Buccal cavity papillomaSystem Organ Class: 100000004864EUCTR2019-003236-23-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc6,000
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageOral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58MedDRA version: 20.0Level: LLTClassification code 10006524Term: Buccal cavity papillomaSystem Organ Class: 100000004864EUCTR2019-003236-23-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.6,000
进行中（未招募）
1 期
Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of ageOral persistent infection caused by any of the human papillomavirus types 16, 18, 31, 33, 45, 52, and 58MedDRA version: 20.0Level: LLTClassification code 10006524Term: Buccal cavity papillomaSystem Organ Class: 100000004864EUCTR2019-003236-23-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc6,000